374 related articles for article (PubMed ID: 16470224)
1. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors.
Wenger T; Mattern J; Penzel R; Gassler N; Haas TL; Sprick MR; Walczak H; Krammer PH; Debatin KM; Herr I
Cell Death Differ; 2006 Oct; 13(10):1740-51. PubMed ID: 16470224
[TBL] [Abstract][Full Text] [Related]
2. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Zhang L; Fang B
Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
[TBL] [Abstract][Full Text] [Related]
5. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY
Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand.
Reddy RM; Tsai WS; Ziauddin MF; Zuo J; Cole GW; Maxhimer JB; Fang B; Schrump DS; Nguyen DM
J Thorac Cardiovasc Surg; 2004 Dec; 128(6):883-91. PubMed ID: 15573073
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line.
Zhang L; Gu J; Lin T; Huang X; Roth JA; Fang B
Gene Ther; 2002 Sep; 9(18):1262-70. PubMed ID: 12215894
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
Mori T; Doi R; Toyoda E; Koizumi M; Ito D; Kami K; Kida A; Masui T; Kawaguchi Y; Fujimoto K
Surgery; 2005 Jul; 138(1):71-7. PubMed ID: 16003319
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand.
Hasegawa H; Yamada Y; Harasawa H; Tsuji T; Murata K; Sugahara K; Tsuruda K; Ikeda S; Imaizumi Y; Tomonaga M; Masuda M; Takasu N; Kamihira S
Br J Haematol; 2005 Jan; 128(2):253-65. PubMed ID: 15638862
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Earel JK; VanOosten RL; Griffith TS
Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
[TBL] [Abstract][Full Text] [Related]
11. Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins.
Hu B; Zhu H; Qiu S; Su Y; Ling W; Xiao W; Qi Y
Biochem Biophys Res Commun; 2004 Dec; 325(4):1153-62. PubMed ID: 15555548
[TBL] [Abstract][Full Text] [Related]
12. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
[TBL] [Abstract][Full Text] [Related]
14. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
[TBL] [Abstract][Full Text] [Related]
15. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
16. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.
Van Geelen CM; de Vries EG; de Jong S
Drug Resist Updat; 2004 Dec; 7(6):345-58. PubMed ID: 15790545
[TBL] [Abstract][Full Text] [Related]
17. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
[TBL] [Abstract][Full Text] [Related]
18. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y; Zhang B
Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
[TBL] [Abstract][Full Text] [Related]
19. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
20. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents.
Arizono Y; Yoshikawa H; Naganuma H; Hamada Y; Nakajima Y; Tasaka K
Br J Cancer; 2003 Jan; 88(2):298-306. PubMed ID: 12610517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
